(Q40779485)

23 September 2017

1 reference

title

Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers (English)

1 reference

23 September 2017

0 references

Talan DA

1

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 December 1993

1 reference

Annals of Emergency Medicine

23 September 2017

published in

1 reference

23 September 2017

volume

22

1 reference

23 September 2017

issue

12

1 reference

23 September 2017

page(s)

1871-1890

1 reference

Nosocomial infections, diagnosis-related groups, and study on the efficacy of nosocomial infection control. Economic implications for hospitals under the prospective payment system

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Analysis of 1,186 Episodes of Gram-Negative Bacteremia in Non-University Hospitals: The Effects of Antimicrobial Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Pathophysiology and treatment of septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Prognosis in acute organ-system failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Role of early fluid resuscitation in pediatric septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

The risk factors, incidence, and prognosis of ARDS following septicemia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

STUDIES ON THE FLEXNER GROUP OF DYSENTERY BACILLI : I. THE SPECIFIC ANTIGENS OF SHIGELLA PARADYSENTERIAE (FLEXNER).

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Studies in immuno-chemistry: The isolation and properties of a specific antigenic substance from B. dysenteriae (Shiga)

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Lipopolysaccharide nomenclature--past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Cardiovascular dysfunction in septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Lipopolysaccharides: structural principles and biologic activities

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Studies with Brucella endotoxin in humans: the significance of susceptibility to endotoxin in the pathogenesis of brucellosis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Biological Effects of Bacterial Endotoxins in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Plasma endotoxin concentration in healthy primates and during E. coli-induced shock.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Endotoxemia in human septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Endotoxaemia: an early predictor of septicaemia in febrile patients

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Limitations of the Usefulness of the Limulus Assay for Endotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Endotoxin: detection and clinical significance.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Serial quantitation of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Impact of molecular biology on Pseudomonas aeruginosa immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Immunotherapy of gram-negative bacterial sepsis. A single murine monoclonal antibody provides cross-genera protection.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Production and characterisation of mouse monoclonal antibodies reacting with the lipopolysaccharide core region of gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Studies of an antiendotoxin antibody in preventing the physiologic changes of endotoxemia in awake sheep.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Failure of monoclonal antibodies to core glycolipid to bind intact smooth strains of Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

The pathogenesis of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon- , and Interferon- in the Serum of Patients with Septic Shock

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Tumor necrosis factor and disease severity in children with falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Detection of circulating tumor necrosis factor after endotoxin administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Activation of coagulation after administration of tumor necrosis factor to normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Negative inotropic effects of cytokines on the heart mediated by nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Septic shock: treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Monoclonal antibody to TNF in severe septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynaecological origin

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Preliminary Study on Treatment of Septic Shock Patients with Antilipopolysaccharide IgG from Blood Donors

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Treatment of Gram-Negative Septic Shock with Human IgG Antibody to Escherichia coli J5: A Prospective, Double-Blind, Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Controversies in the use of passive immunotherapy for bacterial infections in the critically ill patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

A critical evaluation of new agents for the treatment of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Anti-endotoxin monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Anti-endotoxin monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Predicting bacteremia in hospitalized patients. A prospectively validated model

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Bacteremia in febrile children seen in a "walk-in" pediatric clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Bacteremia in febrile children under 2 years of age: results of cultures of blood of 600 consecutive febrile children seen in a "walk-in" clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Febrile infants: predictors of bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

A comparative study of the prevalence, outcome, and prediction of bacteremia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Blood cultures in private pediatric practice: an eleven-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Management of infants at risk for occult bacteremia: a decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Strategies for diagnosis and treatment of children at risk for occult bacteremia: clinical effectiveness and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

The systemic septic response: does the organism matter?

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Septic shock: pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Aerobic and anaerobic bacteria in diabetic foot ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Infections associated with biliary drainage procedures in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Microbiological analysis of sepsis complicating non-surgical biliary drainage in malignant obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Antimicrobial Synergism in the Therapy of Gram-Negative Rod Bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Gram-negative bacteremia: variable clinical course and useful prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Clinical trials of immunotherapy for sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

Multiple system organ failure and the sepsis syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2980417-2

7 January 2021

10.1016/S0196-0644(05)80417-2

Identifiers

DOI

1 reference

23 September 2017

1 reference